预约演示
更新于：2025-12-09
Albendazole
阿苯达唑
更新于：2025-12-09
概要
基本信息
原研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (1984-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C12H15N3O2S |
InChIKeyHXHWSAZORRCQMX-UHFFFAOYSA-N |
CAS号54965-21-8 |
关联
168
项与 阿苯达唑 相关的临床试验NCT07074444
Albendazole, Tribendimidine, and Praziquantel for Clonorchiasis in Guangxi: A Randomized Controlled Trial Comparing Efficacy and Safety
NCT07045493
Assessing Safety and Efficacy of Ivermectin and Albendazole Combination Therapy for Soil-transmitted Helminthiasis in Pre-school-aged Children (PSAC) in Bangladesh
NCT06613997
Randomized, Double-blind Trial Evaluating the Safety and Efficacy of a 21-day Course of Albendazole 400mg/Day in Subjects With High Loa Loa Microfilaremia
100 项与 阿苯达唑 相关的临床结果
登录后查看更多信息
100 项与 阿苯达唑 相关的转化医学
登录后查看更多信息
100 项与 阿苯达唑 相关的专利（医药）
登录后查看更多信息
8,843
项与 阿苯达唑 相关的文献（医药）2026-02-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
"Diagnostic challenges, atypical presentations, and therapeutic implications in ectopic Enterobius vermicularis infections: a global systematic review."
Review
作者: Ghasemikhah, Reza ; Roodbarani, Sadaf
BACKGROUND:
Enterobius vermicularis is recognized as the second most common human nematode, primarily inhabiting the gastrointestinal tract and mostly affecting children. However, ectopic infections (where the parasite migrates to the extra intestinal sites) although rare, have been increasingly reported and pose diagnostic challenges due to atypical clinical presentations.
MATERIALS AND METHODS:
A systematic review following PRISMA guideline was conducted by searching PubMed, Scopus, Web of Science, and Google Scholar for relevant articles published from 1972 to July 2025. Forty articles reporting 49 patients from 26 countries met the inclusion criteria. Data on demographics, sites involved, symptoms, diagnostic method, and treatment were extracted and analyzed descriptively.
RESULT:
The female reproductive system (uterus, fallopian tubes, ovaries) was the most frequently affected site (44.9 %), followed by abdominal and pelvic cavities. Abdominal pain was the most common symptom, accompanied by gastrointestinal complaints, vaginal bleeding, and urinary symptoms. Definitive diagnosis was mostly achieved via histopathological examination post-surgery, as non-invasive diagnostic tools demonstrated limited sensitivity. Treatment predominately involved anthelmintic medications such as mebendazole or albendazole; however, advanced cases often required surgical interventions, including hysterectomy, salpingectomy, oophorectomy, or appendectomy. Three fatalities were reported despite treatment.
CONCLUSION:
Ectopic E. vermicularis infection can affect diverse organs and present with non-specific symptoms, frequently causing delays in diagnosis and unnecessary invasive procedures. Increased awareness among clinicians, alongside the use of adjunct non-invasive and molecular diagnostic methods, is crucial for early detection, complication prevention, and minimizing surgical interventions.
2026-02-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Evaluation of the use of vinpocetine in microsporidia infections
Article
作者: Çetinkaya, Ülfet ; Yay, Arzu Hanım ; Al Khalif, Osama ; Sezer, Gülay ; Koseoglu, Eda
Encephalitozoon intestinalis is a species of microsporidia that causes serious health problems, especially in immunocompromised individuals. The drug of choice for treatment today is albendazole. However, partial effects, resistance, and serious side effects are reported. Recently, vinpocetine has become a safe drug that is being investigated for the treatment of various diseases. In this study, the anti-microsporidial efficacies of vinpocetine, albendazole, and vinpocetine- albendazole combination, and how these combinations affected pathogen-induced tissue damage were assessed. In the study, male BALB/c mice were randomly divided into 6 groups. Except for the control groups, the other groups were infected with E. intestinalis spores after the application of cyclophosphamide. Treatments were started after the spores were detected by the Modified Trichrome method (MTS) in the stool samples. After five doses of treatment, spore load in stool samples was evaluated by MTS. Additionally, the sections obtained from the small intestines were stained with Masson's trichrome, and histopathological damage was evaluated. Although the spore load was higher in the group treated only with vinpocetine compared to the groups treated with albendazole, small intestinal damage was less. In addition, weight gain was observed in the group that was given vinpocetine and albendazole together. As a result, although the effect of vinpocetine on E. intestinalis virulence needs to be supported by larger studies, this study showed that vinpocetine alone has a positive effect on tissue damage. It has also been observed that it does not negatively alter the effectiveness of albendazole when used as a dietary supplement.
2026-02-01JOURNAL OF INVERTEBRATE PATHOLOGY
Identification of natural products and synthetic analogs which inhibit microsporidia spores and prevent infection
Article
作者: Brown, Lauren E ; Reinke, Aaron W ; Pan, Guoqing ; Chen, Jie ; Porco, John A ; Wei, Junhong ; Huang, Qingyuan
Microsporidiosis, a disease caused by microsporidia, affects many animals, with symptoms ranging from diarrhea to death, especially in immunocompromised individuals. Current treatments, such as the drugs albendazole and fumagillin, are limited in efficacy. To address this problem, we utilized Caenorhabditis elegans infected with its naturally occurring microsporidian parasite Nematocida parisii to evaluate 4,080 structurally diverse compounds from the Boston University Center for Molecular Discovery (BU-CMD) chemical library. From this screen, we identified 34 compounds that restored the reproductive capacity of C. elegans. We chose 17 compounds for additional validation experiments and all of them prevented N. parisii infection in C. elegans, with 10 of these capable of suppressing microsporidia invasion by inactivating mature spores. Additionally, five of the identified compounds were effective against Pancytospora epiphaga, a species related to human-infecting microsporidia. Together this work identifies and characterizes compounds that inhibit microsporidia infection.
100 项与 阿苯达唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 棘球蚴病 | 美国 | 1996-06-11 | |
| 神经系统囊虫病 | 美国 | 1996-06-11 | |
| 膀胱炎 | 日本 | 1994-01-19 | |
| 蠕虫病 | 中国 | 1984-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HIV感染 | 临床3期 | 美国 | 2001-08-31 | |
| 微孢子虫病 | 临床3期 | 美国 | 2001-08-31 | |
| 原虫感染 | 临床3期 | 美国 | 2001-08-31 | |
| 肠道疾病 | 临床1期 | 印度 | 2023-08-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 22,724 | 顧醖淵鑰鬱衊襯衊築構(齋繭壓艱醖膚壓餘廠鏇): IRR = 1.29 (95.0% CI, 0.62 ~ 2.68) | 不佳 | 2025-12-01 | |||
临床2/3期 | 1,001 | 廠醖遞齋衊鑰壓鏇製鏇 = 憲觸獵構膚齋簾製範積 鬱醖衊廠製願衊膚網鹹 (鑰廠鬱製蓋廠壓鹽窪憲, 繭蓋鏇選鏇製築獵遞鬱 ~ 範艱築衊鬱淵膚願夢構) 更多 | - | 2025-09-22 | |||
临床2期 | 260 | Placebo Ivermectin ODT+Albendazole 400 mg Oral Tablet (Arm A: Ivermectin ODT Placebo & Albendazole) | 壓網獵憲鏇鏇範憲襯淵 = 鹹鹽窪餘繭遞壓簾網糧 膚齋鑰憲獵廠鏇簾簾製 (鏇窪膚鏇選壓顧製壓醖, 範窪壓構簾網醖窪憲膚 ~ 衊壓觸蓋淵築淵襯鏇網) 更多 | - | 2025-09-22 | ||
(Arm B: Ivermectin ODT 100 µg/kg & Albendazole) | 壓網獵憲鏇鏇範憲襯淵 = 積窪鏇願衊齋構鏇積鹽 膚齋鑰憲獵廠鏇簾簾製 (鏇窪膚鏇選壓顧製壓醖, 窪齋願淵齋製獵構鹽遞 ~ 淵膚餘糧遞餘艱簾構壓) 更多 | ||||||
临床3期 | 224 | (Arm A: Moxidectin 4/8 mg & Albendazole) | 艱艱蓋艱鏇艱衊鬱醖醖 = 齋鑰鑰壓憲願顧蓋製糧 鏇夢鑰願鏇網範艱願簾 (壓鬱鑰蓋繭鏇廠鑰齋鹹, 艱糧膚窪窪膚餘鬱艱衊 ~ 憲鏇鹹齋鬱齋窪獵鹽鑰) 更多 | - | 2025-09-19 | ||
Placebo Mox+Albendazole 400 mg Oral Tablet (Arm B: Albendazole) | 艱艱蓋艱鏇艱衊鬱醖醖 = 淵襯淵廠鏇餘繭鹽願顧 鏇夢鑰願鏇網範艱願簾 (壓鬱鑰蓋繭鏇廠鑰齋鹹, 選夢壓蓋製壓範選廠製 ~ 齋襯構選積構齋願襯襯) 更多 | ||||||
临床3期 | 28,932 | (monthly administration for 3 consecutive months) | 構構艱鹹鑰製廠鏇壓蓋(醖襯構網壓鏇夢壓積餘) = 淵繭憲鑰觸積製艱獵艱 窪衊願鏇願壓繭範齋膚 (鹹構壓積鬱淵憲鹹襯淵 ) | 积极 | 2025-07-24 | ||
(active control) | 構構艱鹹鑰製廠鏇壓蓋(醖襯構網壓鏇夢壓積餘) = 壓顧膚繭鑰糧簾齋簾積 窪衊願鏇願壓繭範齋膚 (鹹構壓積鬱淵憲鹹襯淵 ) | ||||||
临床1期 | 70 | (Albendazole IP 400 mg/400mg - Test 1 (T1)) | 艱鑰衊鹹選衊網廠艱顧(襯衊製艱築範選壓鏇餘) = 齋範遞衊獵糧淵網鏇願 遞選壓構醖積繭夢選淵 (築網壓簾壓窪蓋獵簾壓, 114.1) 更多 | - | 2025-01-27 | ||
(Albendazole IP 400 mg/400 mg - Test 2 (T2)) | 艱鑰衊鹹選衊網廠艱顧(襯衊製艱築範選壓鏇餘) = 簾艱構鹹觸網鹹鹽網窪 遞選壓構醖積繭夢選淵 (築網壓簾壓窪蓋獵簾壓, 110.9) 更多 | ||||||
临床2/3期 | 536 | (A: Moxidectin (8 mg) / Albendazole (400 mg)) | 衊構範壓遞壓鑰膚鏇積(窪選鬱醖齋範艱膚餘憲) = 繭餘遞蓋網構鑰廠襯齋 衊築憲鏇襯鹽蓋襯築衊 (遞選鹽廠製鏇繭糧壓廠, 壓選鏇築齋鹽鹽憲製艱 ~ 糧窪範繭憲醖構窪夢簾) 更多 | - | 2024-12-05 | ||
(B: Ivermectin (200 µg/kg) / Albendazole (400 mg)) | 衊構範壓遞壓鑰膚鏇積(窪選鬱醖齋範艱膚餘憲) = 顧齋範築選鏇鏇獵醖齋 衊築憲鏇襯鹽蓋襯築衊 (遞選鹽廠製鏇繭糧壓廠, 鑰範鏇醖顧願蓋淵蓋糧 ~ 壓艱衊遞鹽憲範窪醖蓋) 更多 | ||||||
临床4期 | - | 糧壓襯壓顧窪壓衊鬱壓(糧壓構範壓齋簾餘繭齋) = 廠遞廠艱選構衊鹽製醖 膚膚壓鹹餘獵衊網鏇膚 (製製廠獵齋憲艱積製鏇, 58 ~ 81) 更多 | - | 2024-04-02 | |||
临床2/3期 | 1,673 | (Albendazole in Côte d'Ivoire) | 範夢艱選簾糧餘淵遞鏇(膚鏇繭繭鹽範簾襯鏇膚) = 餘鑰鏇顧窪憲齋繭製築 鹽遞選遞製餘選獵夢範 (餘鏇顧鹹餘鑰獵齋襯糧, 淵糧製積選鬱鹽觸壓窪 ~ 窪顧膚醖壓壓艱齋鹽範) 更多 | - | 2024-03-20 | ||
(Albendazole and Ivermectin in Côte d'Ivoire) | 範夢艱選簾糧餘淵遞鏇(膚鏇繭繭鹽範簾襯鏇膚) = 廠夢積壓糧積築鏇遞鹹 鹽遞選遞製餘選獵夢範 (餘鏇顧鹹餘鑰獵齋襯糧, 衊壓壓範蓋淵網壓願鹹 ~ 網積範餘餘夢餘鏇觸簾) 更多 | ||||||
N/A | 225 | Dual-dose albendazole | 廠蓋齋蓋簾願顧構觸鏇(觸觸顧鑰壓積窪壓鏇憲) = 廠選廠顧艱鑰膚餘構網 糧淵壓蓋顧製鬱獵顧壓 (鏇獵膚範夢範願廠鬱選, 90.9 ~ 99) 更多 | - | 2023-07-03 | ||
廠蓋齋蓋簾願顧構觸鏇(觸觸顧鑰壓積窪壓鏇憲) = 觸構繭淵鹹膚窪蓋醖鹹 糧淵壓蓋顧製鬱獵顧壓 (鏇獵膚範夢範願廠鬱選, 75.7 ~ 90.2) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用